Chronic Graft-Versus-Host Disease (cGVHD)Phase 2NCT06619561
A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD)
A Phase 2 study testing Vimseltinib in people with Chronic Graft-Versus-Host Disease (cGVHD), run by Deciphera Pharmaceuticals, LLC at 26 sites in United States.
Trial summary
The purpose of this study is to determine if vimseltinib is safe, tolerable and works effectively to treat adults with active moderate to severe cGVHD. Participants will be treated with vimseltinib in 28-day treatment cycles for approximately 2 years. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Chronic Graft-Versus-Host Disease (cGVHD)
- What is being tested?
- Vimseltinib
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 48 participants
- Where
- 26 sitesUnited States
- Study dates
- 21 Nov 2024to Oct 2029
- Phase
- Phase 2
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Must be allogeneic hematopoietic stem cell transplant (HSCT) recipients with moderate to severe cGVHD requiring systemic immune suppression.
- May have persistent active acute GVHD (aGVHD) and chronic GVHD (cGVHD) manifestations (overlap syndrome).
- Participants with active cGVHD who have received and failed at least 2 prior lines of systemic therapy.
- Stable dose of systemic corticosteroids is permitted but not required. If being taken, participants should be on a stable dose of corticosteroids for at least 2 weeks prior to starting study drug treatment.
- Adequate organ and bone marrow functions.
- Participants of reproductive potential agree to follow the contraception requirements.
- Karnofsky Performance Scale (KPS) of ≥60.
Who cannot join
- Has aGVHD without manifestations of cGVHD.
- Prior use of colony-stimulating factor 1 receptor (CSF1R) inhibitor for cGVHD.
- History or other evidence of severe illness, uncontrolled infection, or any other conditions that would make the participant unsuitable for the study. All wounds must be healed and free of infection or dehiscence.
- History of malignancy except for:
- Underlying malignancy for which the transplant was performed
- Malignancy treated with curative intent and with no evidence of active disease present for more than 3 years prior to enrollment and felt to be at low risk for recurrence.
- Malabsorption syndrome or other illness that could affect oral absorption.
Trial locations and contacts
26 sites in 1 country. Contact the study team or a site near you to ask about taking part.
26 sites in 1 country
United States26 sites, 26 recruiting
- Recruiting
Emory University Winship Cancer Institute
Atlanta, Georgia, 30322
- Recruiting
St. David's South Austin Medical Center
Austin, Texas, 78704
- Recruiting
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215
- Recruiting
Levine Cancer Institute
Charlotte, North Carolina, 28204
- Recruiting
University of Illinois Medical Center - Hematology & Oncology
Chicago, Illinois, 60612
- Recruiting
Oncology Hematology Care Clinical Trials, LLC
Cincinnati, Ohio, 45242
- Recruiting
Cleveland Clinic
Cleveland, Ohio, 44195
- Recruiting
The Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210
- Recruiting
UT Southwestern Medical Center
Dallas, Texas, 75390
- Recruiting
Henry Ford Cancer Institute
Detroit, Michigan, 48202
- Recruiting
City of Hope National Medical Center
Duarte, California, 91010
- Recruiting
Duke University Hospital
Durham, North Carolina, 27705
- Recruiting
University of Kentucky Markey Cancer Center
Lexington, Kentucky, 40536
- Recruiting
Ronald Regan UCLA Medical Center
Los Angeles, California, 90095
- Recruiting
Tristar Bone Marrow Transplant
Nashville, Tennessee, 37203
- Recruiting
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee, 37232
- Recruiting
University of California Irvine Health
Orange, California, 92868-3201
- Recruiting
AdventHealth Orlando
Orlando, Florida, 32804
- Recruiting
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania, 15232
- Recruiting
Oregon Health and Science University
Portland, Oregon, 97239
- Recruiting
Virginia Commonwealth University
Richmond, Virginia, 23298
- Recruiting
Intermountain Health
Salt Lake City, Utah, 84143
- Recruiting
Avera Cancer Institute
Sioux Falls, South Dakota, 57105
- Recruiting
Washington University School of Medicine - Siteman Cancer Center
St Louis, Missouri, 63108
- Recruiting
Moffitt Cancer Center
Tampa, Florida, 33612
- Recruiting
University of Kansas Cancer Center-Westwood
Westwood, Kansas, 66205
About this study
Official title: A Phase 2, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, PK, and Efficacy of Vimseltinib in Adults With Active Chronic GVHD After Failure of Prior Systemic Therapy
The purpose of this study is to determine if vimseltinib is safe, tolerable and works effectively to treat adults with active moderate to severe cGVHD. Participants will be treated with vimseltinib in 28-day treatment cycles for approximately 2 years.
- Being tested
- Vimseltinib
- Keywords
- Allogeneic hematopoietic stem cell transplant (HSCT), Graft-Versus-Host Disease, GVHD, cGVHD, Graft versus host disease, Immune System Diseases, Organizing Pneumonia, Bronchiolitis Obliterans, Bronchiolitis, Bronchial Diseases, Respiratory Tract Diseases, Lung Diseases, Obstructive, Lung Diseases, Bronchiolitis Obliterans Syndrome, Graft vs Host Disease, Sclerosis, Fibrosis, Hematopoietic stem cell transplantation, Liver diseases
- Medical subject headings
- Bronchiolitis Obliterans Syndrome, Graft vs Host Disease, Immune System Diseases, Organizing Pneumonia, Bronchiolitis Obliterans, Bronchiolitis, Bronchial Diseases, Respiratory Tract Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
VimseltinibDrug
Also called DCC-3014
Administered orally
| Study group | Role | What they receive |
|---|---|---|
| Vimseltinib | Experimental | Escalating doses of vimseltinib in 28 day cycles. Receives: Drug: Vimseltinib |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of Participants with Dose-Limiting Toxicities (DLTs)
DLTs assessed for each dose level.
Measured: Cycle 1 (28 Days)
Number of Participants with Adverse Event(s) (AEs) and Serious Adverse Event(s) (SAEs)
AEs and SAEs assessed for each dose level.
Measured: Baseline to Study Completion (Estimated up to 24 months)
Secondary outcomes (5)
Objective Response Rate (ORR)
ORR is percentage of participants achieving best overall response of complete response (CR) or partial response (PR) up to Cycle 7 Day 1 based on 2014 National Institutes of Health (NIH) cGVHD Criteria.
Measured: Baseline up to Cycle 7 Day 1 (Cycle = 28 days)
Duration of Response (DOR)
DOR for participants with CR or PR, defined as the time interval from the time of first CR or PR per 2014 NIH cGVHD Criteria, until PD, initiation of new systemic therapy for cGVHD, or death due to any cause, whichever occurs first.
Measured: First CR or PR until PD or Death due to Any Cause (Estimated up to 24 months)
Organ-Specific Response
Organ-specific response per 2014 NIH cGVHD Criteria up to Cycle 7 Day 1
Measured: Baseline up to Cycle 7 Day 1 (Cycle = 28 days)
Failure-Free Survival (FFS)
FFS is the time from first dose to progressive disease (PD) per 2014 NIH cGVHD Criteria, initiation of new systemic therapy for cGVHD, or death due to any cause, whichever occurs first.
Measured: Baseline to, whichever occurs first of, PD, Addition of Systemic Immune Suppressive Therapy, or Death due to Any Cause (Estimated up to 24 months)
Pharmacokinetics (PK): Maximum Observed Plasma Concentration (Cmax)
Cmax
Measured: Estimated up to 24 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Oct 2024
- Study start21 Nov 2024
- Primary completionOct 2029 (estimated)
- Study completionOct 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Chronic Graft-Versus-Host Disease (cGVHD)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 48 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Deciphera Pharmaceuticals, LLC
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Clinical Team, Study director, Deciphera Pharmaceuticals, LLC
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06619561
- Sponsor's protocol ID
- DCC-3014-02-001
- Status last verified
- Dec 2025
- First submitted
- 27 Sep 2024
- Last updated
- 15 Dec 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 15 Dec 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase 2, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, PK, and Efficacy of Vimseltinib in Adults With Active Chronic GVHD After Failure of Prior Systemic Therapy
- ClinicalTrials.gov ID
- NCT06619561
- Acronym / sponsor ID
- DCC-3014-02-001
- Keywords
- Allogeneic hematopoietic stem cell transplant (HSCT), Graft-Versus-Host Disease, GVHD, cGVHD, Graft versus host disease, Immune System Diseases, Organizing Pneumonia, Bronchiolitis Obliterans
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 48 participants (estimated)
- Lead sponsor
- Deciphera Pharmaceuticals, LLCIndustry (pharma, biotech, devices)
- Study start
- 21 Nov 2024 (actual)
- Primary completion
- Oct 2029 (estimated)
- Study completion
- Oct 2029 (estimated)
- First posted
- 1 Oct 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to determine if vimseltinib is safe, tolerable and works effectively to treat adults with active moderate to severe cGVHD. Participants will be treated with vimseltinib in 28-day treatment cycles for approximately 2 years.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Vimseltinib | Experimental | Drug: VimseltinibEscalating doses of vimseltinib in 28 day cycles. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (7 listed)
- Must be allogeneic hematopoietic stem cell transplant (HSCT) recipients with moderate to severe cGVHD requiring systemic immune suppression.
- Participants with active cGVHD who have received and failed at least 2 prior lines of systemic therapy.
- Stable dose of systemic corticosteroids is permitted but not required. If being taken, participants should be on a stable dose of corticosteroids for at least 2 weeks prior to starting study drug treatment.
- Adequate organ and bone marrow functions.
- Participants of reproductive potential agree to follow the contraception requirements.
Key exclusion criteria (7 listed)
- Has aGVHD without manifestations of cGVHD.
- Prior use of colony-stimulating factor 1 receptor (CSF1R) inhibitor for cGVHD.
- History or other evidence of severe illness, uncontrolled infection, or any other conditions that would make the participant unsuitable for the study. All wounds must be healed and free of infection or dehiscence.
- History of malignancy except for:
- Malabsorption syndrome or other illness that could affect oral absorption.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| VimseltinibAlso: DCC-3014Administered orally | Drug | Vimseltinib |
Primary outcome
Number of Participants with Dose-Limiting Toxicities (DLTs)
Time frame: Cycle 1 (28 Days)
DLTs assessed for each dose level.
Number of Participants with Adverse Event(s) (AEs) and Serious Adverse Event(s) (SAEs)
Time frame: Baseline to Study Completion (Estimated up to 24 months)
AEs and SAEs assessed for each dose level.
5 secondary outcomes
Objective Response Rate (ORR)
Time frame: Baseline up to Cycle 7 Day 1 (Cycle = 28 days)
Duration of Response (DOR)
Time frame: First CR or PR until PD or Death due to Any Cause (Estimated up to 24 months)
Organ-Specific Response
Time frame: Baseline up to Cycle 7 Day 1 (Cycle = 28 days)
Failure-Free Survival (FFS)
Time frame: Baseline to, whichever occurs first of, PD, Addition of Systemic Immune Suppressive Therapy, or Death due to Any Cause (Estimated up to 24 months)
Pharmacokinetics (PK): Maximum Observed Plasma Concentration (Cmax)
Time frame: Estimated up to 24 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 Dec 2025.
Related trials for Chronic Graft-Versus-Host Disease (cGVHD)
RecruitingObservational study
Evaluation of Patients With Immune Function Abnormalities
Chronic Granulomatous Disease (CGD), X-Linked Severe Combined Immune Deficiency (XSCID)
Not yet recruitingObservational study
Effects of Axatilimab on Skin in Chronic Graft-versus-Host Disease
Chronic Graft vs. Host Disease, GVHD
RecruitingPhase 2
Ruxolitinib vs Prednisone as First-line Therapy for cGVHD Needing Systemic Therapy
Chronic Graft-versus-host Disease (cGVHD)
RecruitingPhase 2
Axatilimab in Combination With Extracorporeal Photopheresis (ECP) in Chronic Graft-versus-Host Disease
Chronic Graft Versus Host Disease, cGVHD
Active, not recruiting
Tele-Palliative Care Intervention for Patients With Chronic Graft-Versus-Host Disease
Chronic Graft-versus-host Disease, Chronic GVHD
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Clinical Team study director
Deciphera Pharmaceuticals, LLC
26 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing Vimseltinib in people with Chronic Graft-Versus-Host Disease (cGVHD), run by Deciphera Pharmaceuticals, LLC at 26 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 15 Dec 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 26 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Clinical Team (888-724-3274, clinicaltrials@deciphera.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of Participants with Dose-Limiting Toxicities (DLTs) (time frame: Cycle 1 (28 Days)). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Dec 2025; AzTrials last refreshed its copy on 1 Nov 2026.